



   
Cancer Prone Disease Section 
Short Communication 
 
Atlas Genet Cytogenet Oncol Haematol. 2013; 17(10)  726 
INIST-CNRS 
 
OPEN ACCESS JOURNAL 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
Paget's disease of bone 
Stuart H Ralston 
Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Scotland 
(SHR) 
 
Published in Atlas Database: April 2013 
Online updated version : http://AtlasGeneticsOncology.org/Kprones/PagetDiseaseID10057.html 
DOI: 10.4267/2042/51543 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 






Autosomal dominant; polygenic. 
Clinics 
Note 
A family history is found in approximately 15% of 
cases. In such families, the disease is inherited as an 
autosomal dominant trait with about 80-90% 
penetrance by the age of 70. About 50% of patients 
with familial PDB have a mutation in the SQSTM1 
gene and in others there is linkage to a locus on 
chromosome 10p13 (Lucas et al., 2008). The gene 
responsible in this locus remains to be identified. There 
also may be familial clustering without a clear patten of 
inheritance consistent with polygenic inheritance. 
Common genetic variants at seven loci have been 
identified that predispose to Paget's disease (Albagha et 
al., 2011; Albagha et al., 2010), but the causal variants 
have not been identified. Overall relatives of patients 
with Paget's have 7-fold increase risk of developing the 
disease as compared with the general population. 
Phenotype and clinics 
The disease is characterised by focal bone lesions in 
which there is increased osteoclastic bone resorption 
coupled with increase and disorganised new bone 
formation (Ralston, 2013). The axial skeleton is 
predominantly affected. The most common sites are the 
pelvis, spine, femurs, skull and tibia. Many patients are 
asyptomatic and a common mode of presentation is 
with an abnormal serum alkaline phosphatase picked 
up on routine blood tests or an abnormal radiograph.  
The most common complaint in patients who come to  
medical attention is bone pain. Other common 
complications include pathological fractures, bone 
deformity, deafness (when the base of the skull is 
involved), secondary osteoarthritis, and nerve 
compression syndromes (van Staa et al., 2002). Rare
complications include hypercalcaemia which can occur 
if the patient is immobilised and dehydrated and high 
output cardiac failure due to increased blood flow 
through affected bone. 
Neoplastic risk 
The risk of osteosarcoma is increased and it has been 
estimated to occur in about 0.3% of patients (Manghm 
et al., 2009).  
This represents more than one thousand fold increase in 
risk as compared with adults in the general population 
(van Staa et al., 2002). The osteosarcoma arises in 
affected bones. 
Treatment 
Paget's disease can be treated with bisphosphonates 
which supress the elevated bone turnover and can 
improve pain. Orthopaedic surgery may be required for 
the treatment of fractures, secondary osteoarthritis and 
spinal stenosis. Surgical excision and chemotherapy 
may be required for osteosarcoma. 
Prognosis 
Bisphosphonates are often effective at helping bone 
pain but it is uncertain at present if they alter the 
natural history of Paget's or prevent complications. The 
prognosis is poor for patients who develop 
osteosarcoma, even with agressive treatment (Sharma 
et al., 2005). 
Cytogenetics 
Note 
No cytogenetic abnormalities have been identified in 
Paget's. 
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Cytogenetics of cancer 
Multiple chromosomal abberations have been described 
in osteosarcoma, but none are specific for Paget's 
disease. 






The human gene contains 8 exons and spans 31.6 Kb of 
genomic DNA. There are three mRNA transcripts. The 
predominant transcript is NM_003900 which comprises 
2923 bp. Two other transcripts have been identified. 
One (NM_001142298.1) of 2931 bp differs from 
NM_003900 in the 5' UTR, lacks a portion of the 5' 
coding region, and initiates translation from an in-
frame downstream start codon compared to another 
variant 1. This results in an isoform with a shorter N-
terminus compared to NM_003900. A third transcript 
(NM_001142299) of 2848 bp differs from 




The p62 protein contains 440 amino acids and has a 
mass of 47 Kda. It contains several domains, uncluding 
a TRAF-6 binding domain, a ubiquitin associated 
domain and SH2 domains. 
Expression 
Widely expressed in many cells and tissues. 
Function 
The p62 protein is an adaptor protein involved in NFkB 
signalling downstream of the RANK receptor, TNF 
receptor, IL-1 receptor and NGF receptor. In RANK 
signaling is responsible for recruiting CYLD to the 
intracellular receptor complex and this requires a 
functional UBA domain. 
Mutations 
Note 
More than 25 mutations of SQSTM1 have been 
described in Patients with Paget's disease and most of 
these affect the UBA domain (Ralston and Layfield, 
2012). Functional analysis indicates that most 
mutations impair the ability of the UBA domain to bind 
ubiquitin chains (Goode and Layfield, 2010). 
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